Their findings suggested that nuclear factor-kappa B (NF-kB) activation could suppress TET1 via p65 binding, with low TET1 expression correlating with elevated immune markers in basal-like breast cancer tissues. The gene discussed is TET1; the disease is breast carcinoma.